Literature DB >> 11694207

Oral nicotine solution for smoking cessation: a pilot tolerability study.

E C Westman1, K F Tomlin, C E Perkins, J E Rose.   

Abstract

This study was conducted to determine the preliminary tolerability of an oral nicotine solution with minimal behavioral intervention for smoking cessation. Twenty-five healthy volunteers who smoked at least 10 cigarettes per day and were motivated to quit smoking were enrolled in an open-labeled trial with a 12-week treatment and a 6-month follow-up period. After reviewing self-help materials and setting a quit-smoking day, subjects were provided nicotine solution to mix with their beverages to control smoking urges, and returned for refills eight times over 12 weeks. Abstinence (point prevalence) was defined as self-report of 0 cigarettes smoked for the previous 7 days verified by exhaled carbon monoxide (CO) <10 ppm. The oral nicotine solution was well tolerated when mixed with an individual's chosen beverage. Subjects controlled the concentration of nicotine consumed, which ranged from 0.25 to 10 mg nicotine base per 170-354 ml of beverage. One week after the quit date the mean venous nicotine level was 13.4 ng/ml and mean serum cotinine level was 418.0 ng/ml in six non-smokers. Abstinence rates at 4 weeks, 3 months, and 6 months were 28.0%, 24.0%, and 20.0%, respectively. It was concluded that an oral nicotine solution was tolerable and provided nicotine replacement at levels that may prove useful for smoking cessation. Further research to clarify appropriate dosages and optimal beverages for mixture, and controlled trials to assess safety and efficacy, appear in order.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11694207     DOI: 10.1080/14622200126973

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  7 in total

1.  Pharmacokinetic and pharmacodynamics studies of nicotine after oral administration in mice: effects of methoxsalen, a CYP2A5/6 inhibitor.

Authors:  Shakir D Alsharari; Eric C K Siu; Rachel F Tyndale; Mohamad Imad Damaj
Journal:  Nicotine Tob Res       Date:  2013-07-24       Impact factor: 4.244

2.  Individual differences in oral nicotine intake in rats.

Authors:  Tanseli Nesil; Lutfiye Kanit; Allan C Collins; Sakire Pogun
Journal:  Neuropharmacology       Date:  2011-04-12       Impact factor: 5.250

Review 3.  Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice.

Authors:  Henri-Jean Aubin; Amandine Luquiens; Ivan Berlin
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

Review 4.  Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status.

Authors:  August R Buchhalter; Reginald V Fant; Jack E Henningfield
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 5.  Guidelines on nicotine dose selection for in vivo research.

Authors:  Shannon G Matta; David J Balfour; Neal L Benowitz; R Thomas Boyd; Jerry J Buccafusco; Anthony R Caggiula; Caroline R Craig; Allan C Collins; M Imad Damaj; Eric C Donny; Phillip S Gardiner; Sharon R Grady; Ulrike Heberlein; Sherry S Leonard; Edward D Levin; Ronald J Lukas; Athina Markou; Michael J Marks; Sarah E McCallum; Neeraja Parameswaran; Kenneth A Perkins; Marina R Picciotto; Maryka Quik; Jed E Rose; Adrian Rothenfluh; William R Schafer; Ian P Stolerman; Rachel F Tyndale; Jeanne M Wehner; Jeffrey M Zirger
Journal:  Psychopharmacology (Berl)       Date:  2006-08-09       Impact factor: 4.530

Review 6.  Novel delivery systems for nicotine replacement therapy as an aid to smoking cessation and for harm reduction: rationale, and evidence for advantages over existing systems.

Authors:  Lion Shahab; Leonie S Brose; Robert West
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

Review 7.  New Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline?

Authors:  Emma Beard; Lion Shahab; Damian M Cummings; Susan Michie; Robert West
Journal:  CNS Drugs       Date:  2016-10       Impact factor: 5.749

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.